AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Deals

$2.5B Teneobio Deal Complements Amgen’s Core and Capabilities

Amgen will gain Teneobio’s proprietary bispecific and multispecific antibody technologies, which have the potential to target multiple diseases across Amgen’s core therapeutic areas.

July 28, 2021

3 min read

Alex Keown

Allergan eye drops are showing promising results i

Drug Development

Allergan Eye Drops for Presbyopia Hits All Endpoints, Focuses In on Approval

The company said its Allergan eye drops met both its primary and key secondary endpoints, with patients reporting near and intermediate improvements in vision.

July 26, 2021

3 min read

Vanessa Doctor, RN

Job Trends

The BioMidwest Region Features Lifestyle Bonuses and Cutting-Edge Science

Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?

July 26, 2021

4 min read

Heather McKenzie

Courtesy of Smith Collection/Gado/Getty Images

FDA

FDA Greenlights AbbVie’s Antibiotic Dalvance for Acute Skin Infections in Children

The U.S. Food and Drug Administration (FDA) approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients as young as newborns.

July 23, 2021

3 min read

Mark Terry

Pharm Country

BioSpace’s Business Report Highlights Sustained Growth and New Blood

The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.

July 22, 2021

5 min read

Heather McKenzie

Drug Development

Genentech’s Combo Therapy for Rare Blood Cancers Scores Breakthrough Designation

Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.

July 21, 2021

2 min read

Vanessa Doctor, RN

Job Trends

Frontier Medicines Raises $88.5 Million to Advance Chemoproteomics Program

Frontier Medicines will support the continued development of the company’s chemoproteomics drug discovery program, including lead asset, an inhibitor of KRASG12C.

July 19, 2021

3 min read

Alex Keown